C. Ward < C. Warren Olanow < C. Waterman

Facettes :

List of bibliographic references indexed by C. Warren Olanow

Number of relevant bibliographic references: 32.
[20-40] [0 - 20][0 - 32]

Ident.	Authors (with country if any)	Title
001648 (2004)	Matthew B. Stern [États-Unis] ; Kenneth L. Marek [États-Unis] ; Joseph Friedman [États-Unis] ; Robert A. Hauser [États-Unis] ; Peter A. Lewitt [États-Unis] ; Daniel Tarsy [États-Unis] ; C. Warren Olanow [États-Unis]	Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
001709 (2003)	Matthew A. Brodsky [États-Unis] ; James Godbold [États-Unis] ; Tom Roth [États-Unis] ; C. Warren Olanow [États-Unis]	Sleepiness in Parkinson's disease: A controlled study
001719 (2003)	Kevin St. P. Mcnaught [États-Unis] ; C. Warren Olanow [États-Unis]	Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease
001736 (2003)	Fabrizio Stocchi [Italie] ; C. Warren Olanow [États-Unis]	Neuroprotection in Parkinson's disease: Clinical trials
001846 (2002)	Fabrizio Stocchi ; Stefano Ruggieri ; Laura Vacca ; C. Warren Olanow [États-Unis]	Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease
001885 (2002)	Ira Shoulson [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Anthony Lang ; J. William Langston [États-Unis] ; Peter Lewitt [États-Unis] ; C. Warren Olanow [États-Unis] ; John B. Penney ; Caroline Tanner [États-Unis] ; Karl Kieburtz [États-Unis] ; Alice Rudolph [États-Unis]	Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
001942 (2002)	Kevin St P. Mcnaught [États-Unis] ; P. Shashidharan [États-Unis] ; Daniel P. Perl [États-Unis] ; Peter Jenner [Royaume-Uni] ; C. Warren Olanow [États-Unis]	Aggresome‐related biogenesis of Lewy bodies
001C14 (2000)	José A. Obeso [Espagne] ; C. Warren Olanow [États-Unis] ; John G. Nutt [États-Unis]	Levodopa motor complications in Parkinson's disease
001E48 (1998)	Jenner [Royaume-Uni] ; C. Warren Olanow	Understanding cell death in parkinson's disease
001F05 (1998)	C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] ; David Brooks [Royaume-Uni]	Dopamine agonists and neuroprotection in parkinson's disease
002021 (1997)	Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Karen Busenbark [États-Unis] ; Jean Hubble [États-Unis] ; Steve Wilkinson [États-Unis] ; Anthony Lang [Canada] ; Paul Tuite [Canada] ; Elspeth Sime [Canada] ; Andres Lazano [Canada] ; Robert Hauser [États-Unis] ; Teresita Malapira [États-Unis] ; Donald Smith [États-Unis] ; Daniel Tarsy [États-Unis] ; Edison Miyawaki [États-Unis] ; Thorkild Norregaard [États-Unis] ; Theresa Kormos [États-Unis] ; C. Warren Olanow [États-Unis]	High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
002216 (1995)	Thomas B. Freeman [États-Unis] ; Paul R. Sanberg [États-Unis] ; G. Michael Nauert [États-Unis] ; Barbara D. Boss [États-Unis] ; Dennis Spector [États-Unis] ; C. Warren Olanow [États-Unis] ; Jeffrey H. Kordower [États-Unis]	The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts

---

List of associated KwdEn.i

Nombre de documents	Descripteur
13	Parkinson's disease
4	levodopa
3	motor complications
2	dopamine agonists
2	dyskinesia
2	proteasome
2	rasagiline
2	α‐synuclein
1	Abbreviations: AIMS = Abnormal Involuntary Movements Scale; MPTP = 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine; UPDRS = Unified Parkinson’s Disease Rating Scale
1	Clinical trials
1	Delayed start study
1	Disease modification
1	Keywords: lisuride; Parkinson’s disease; randomized trial; prospective trial; dyskinesia
1	Long term simple study
1	L‐dopa
1	MPTP
1	PD
1	PD dementia
1	Prions
1	Proteins
1	advanced Parkinson's disease
1	alpha‐synuclein
1	application and limitation
1	axonal transport
1	basal ganglia
1	centrosome
1	delayed start design
1	diagnostic criteria
1	disease modification
1	dopamine
1	driving
1	dyskinesias
1	emotional processing
1	executive functions
1	familial Parkinson's disease
1	future perspectives
1	magnetic resonance imaging
1	memory
1	monoamine oxidase inhibitors
1	monotherapy
1	motor disability
1	motor fluctuations
1	movement disorders
1	neural repair
1	neurodegeneration
1	neuroprotection
1	neurotoxicity
1	neurotrophic factors
1	oxidative stress
1	pathogenesis
1	pramipexole
1	primate
1	protein accumulation
1	safety
1	sleep episode
1	somnolence
1	task force
1	tolerability
1	transcranial sonography
1	translational research
1	ubiquitin
1	ubiquitin‐proteasome system
1	γ‐tubulin

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i -k "C. Warren Olanow" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i  \
                -Sk "C. Warren Olanow" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Author.i
   |clé=    C. Warren Olanow
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024